Targeted
Medical Pharma, Inc. (OTCQB: TRGM) recently published the White
Paper: Innovations
in Pain Management discussing the epidemic of pain, the dangers
of commonly prescribed pain medications and the benefits of Theramine
as a clinically effective alternative to opioids and nonsteroidal
anti-inflammatory (NSAID) drugs for the management of back pain and
inflammation.
According to Consumer Reports, the overuse of opioid
pain medications has reached epidemic proportions in the United
States, and poses a significant public health problem. Roughly 45 people
a day and more than 16,600 people a year, die from overdoses of these
drugs, including methadone,
morphine,
and oxycodone
(OxyContin) and hydrocodone combined
with acetaminophen (Lortab and Vicodin). On September 30, 2014, the
American Academy of Neurology published their new
position regarding opioids, stating that the risks of opioids
outweigh the benefits for headache, low back pain and other chronic
conditions.
Theramine, a medical
food specially formulated to address the increased amino acid
requirements of pain syndromes, has been used clinically to manage back
pain, migraines, Fibromyalgia and other pain syndromes since 2004 as an
adjunct and replacement therapy to opioid, NSAID and anti-epileptic pain
medications by physicians throughout the United States. Theramine
has been the subject of two double-blind clinical
trials which are published in the American
Journal of Therapeutics. In both studies, Theramine showed a
statistically significant reduction in inflammation and improvement in
low back pain than both naproxen and ibuprofen and proved to be
effective at increasing specific amino acid levels in study subjects.
“The overprescribing of narcotic pain medications and the overuse of
NSAIDs is a growing problem that our company and products can help
address,” said William Shell M.D., CEO and Chief Science Officer at
Targeted Medical Pharma. “Theramine is an effective clinical tool
for physicians interested in managing pain and inflammation without the
GI or cardiovascular side effects associated with NSAIDs or the
addictive potential of narcotics.”
Twitter: @tmedpharma
Facebook: www.facebook.com/targetedmedicalpharma
About Targeted Medical Pharma, Inc.
Targeted
Medical Pharma, Inc. is a publicly traded, Los Angeles-based
biotechnology company that is committed to drug discovery and
development. The company currently develops and distributes amino acid
based medical foods, a rapidly growing sector of medication technology,
for the treatment of chronic disease, including pain syndromes,
peripheral neuropathy, hypertension, obesity, sleep and cognitive
disorders using the patented system of Targeted
Cellular Technology.
The company also develops a line of dietary supplements designed to
support health and wellness. TMP currently manufactures 10 proprietary
amino acid based medical
foods, and recently launched its first dietary supplement, Clearwayz™.
The products are sold directly to physicians and pharmacies in the U.S.
The Company is also developing nutrient-based systems for oral
stimulation of progenitor stem cells that differentiate into neurons,
red blood cells, pituitary hormones including IGF-I.
Forward-Looking Statement
This press release may contain forward-looking statements related to
Targeted Medical Pharma’s business strategy, outlook, objectives, plans,
intentions or goals. The words "may," "will," "should," "plans,"
"explores," "expects," "anticipates," "continue," "estimate," "project,"
"intend," and similar expressions, identify forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of
1995, but their absence does not mean that the statement is not
forward-looking. These statements are not guarantees of future
performance and are subject to certain risks, uncertainties, and
assumptions that are difficult to predict. Actual results could differ
materially. Targeted Medical Pharma expressly disclaims any obligation
or undertaking to update or revise any forward-looking statement
contained herein to reflect any change in the company's expectations
with regard thereto or any change in events, conditions or circumstances
upon which any statement is based.
Copyright Business Wire 2014